We have launched our mobile app, get it now. Call : 9354229384, 9354252518, 9999830584.  

Current Affairs

Filter By Date

Filter By Date

Phase 3 data on Covaxin trials

Date: 23 April 2021 Tags: Miscellaneous

Issue

Bharat Biotech has released the data from its phase 3 studies on the efficacy of its Covid-19 vaccine, Covaxin.

 

Background

The studies conducted on patients are very important in understanding the efficacy of vaccines and also its side-effects.

 

Details

  • The results have shown an interim clinical efficacy of 78 per cent and 100 per cent efficacy in tackling severe Covid-19 disease in phase 3 trials.

  • The vaccine was developed using Whole Virion Inactivated Vero Cell derived platform technology by making use of strains obtained from National Institute of Virology.

  • It is India’s first indigenous vaccine against the Covid-19 disease. It makes use of inactive virus strains that are not capable of infecting but can trigger immune response.

  • The vaccine was approved under Emergency Use Authorisation through a clinical trial mode under phase 1 and phase 2.

 

Analysis of results

  • The results have shown a vaccine efficacy of 78 per cent against mild, moderate, and severe Covid-19 disease.

  • The efficacy of vaccine against severe disease was found to be 100 percent and it reduced the need for hospitalisation significantly.

  • There was efficacy of 70 percent against asymptomatic covid-19 infection that showed lower transmission by recipients of Covaxin.

  • The vaccine has shown neutralising capacity against the Brazil variant, UK variant, South Africa variant and the double mutant Indian strain.